menu ☰
menu ˟

FDA grants orphan drug designation for APTO-253 for AML

05 Jun 2015
The FDA granted orphan drug designation to APTO-253 for the treatment of patients with acute myeloid leukemia, according to a press release from the drug’s manufacturer.APTO-253 (Aptose Biosciences) — a first-in-class inducer of the Krüppel-like...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.